Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs

Bonum Therapeutics, a Seattle-based biomanufacturer, is moving into new offices in South Lake Union and plans to double its workforce in pursuit of producing its new immunotherapy drug for cancer treatment. Using small proteins called cytokines, which tell the immune system where and when to attack, the company is working on a new treatment called Interleukin-2.
“The really exciting thing about working on something like this is that you get to do stuff that will, with any luck, have an impact on people,” said CEO John Mulligan. “A few years from now, we might see people who are living longer because of the stuff we’re doing right now.”
Bonum’s new immunotherapy development and operational expansion are emblematic of Seattle’s dedication to the ongoing battle against cancer and other chronic diseases, bolstered by the influx of the nation’s premier biotech talent.
Photo credit: Alexandria Real Estate Equities.